Author : Naina mohamed pakkir maideen
Keyword : Sulfonylurea, pharmacokinetic interactions, pharmacodynamic interactions, cyp2c9
Subject : Diabetes
Article Type : Review article
DOI : 10.13187/ejm.2018.2.83
Article QR Code
Article File : Full Text PDF
Abstract : Sulfonylureas are useful to treat type 2 diabetes patients. Apart from sulfonylureas, the patients with diabetes may use many other medications to treat various concomitant illnesses such as high blood pressure, higher lipids, infections, pain, etc. The probability of interactions increases with the number of drugs used concomitantly. Most of the adverse drug interactions of sulfonylureas result in hypoglycemia, which can be life threatening. Sulfonylureas are primarily metabolized by CYP2C9 enzyme, which paves the way for most of their pharmacokinetic drug interactions. Drugs inhibiting CYP2C9 enzyme are expected to elevate the plasma concentrations of sulfonylureas and subsequent hypoglycemic complications. Some drugs potentiate the hypoglycemic activity of sulfonylureas pharmacodynamically too. The prescribers and pharmacists must be aware of the adverse drug interactions of sulfonylureas to prevent hypoglycemic episodes.
Article by : Naina Mohamed Pakkir Maideen
Article add date : 2021-12-21
How to cite : Naina mohamed pakkir maideen. (2021-December-21). Pharmacokinetic and pharmacodynamic interactions of sulfonylurea antidiabetics. retrieved from https://www.openacessjournal.com/abstract/934